Browse ACAN

Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF00059 Lectin C-type domain
PF00084 Sushi repeat (SCR repeat)
PF07686 Immunoglobulin V-set domain
PF00193 Extracellular link domain
Function

This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006790 sulfur compound metabolic process
GO:0018146 keratan sulfate biosynthetic process
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0042339 keratan sulfate metabolic process
GO:0042340 keratan sulfate catabolic process
GO:0043062 extracellular structure organization
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0005201 extracellular matrix structural constituent
GO:0005539 glycosaminoglycan binding
GO:0005540 hyaluronic acid binding
GO:0030246 carbohydrate binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3656244: Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
R-HSA-3656225: Defective CHST6 causes MCDC1
R-HSA-3656243: Defective ST3GAL3 causes MCT12 and EIEE15
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022854: Keratan sulfate biosynthesis
R-HSA-2022857: Keratan sulfate degradation
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACAN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACAN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACAN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8970.0213
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4310.0258
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.520.349
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3680.412
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8590.702
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2570.931
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9580.134
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6910.47
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.4470.134
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4490.703
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6810.641
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1340.505
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACAN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.86.880.252
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.127.3-4.21
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.214.8-1.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.623.1-9.50.648
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACAN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACAN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACAN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACAN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACAN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACAN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACAN
Nameaggrecan
Aliases CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ......
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACAN collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ACAN.
ID Name Drug Type Targets #Targets
DB02255GM6001Small MoleculeACAN, ADAM282